Methotrexate Effectively Controls Ocular Inflammation in Japanese Patients With Non-infectious Uveitis.
Japanese
immunosuppressive therapy
intraocular inflammation
methotrexate
non-infectious uveitis
uveitis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
06
2021
accepted:
20
10
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
epublish
Résumé
This single-center retrospective study investigated the clinical characteristics and efficacy of methotrexate (MTX) for the treatment of non-infectious uveitis for more than 6 months at Hiroshima University, from February 2016 to May 2021. Outcome variables included changes in systemic immunosuppressive treatment and intraocular inflammation. Out of 448 patients with non-infectious uveitis, 35 patients (14 male patients and 21 female patients; 65 eyes) treated with MTX for more than 6 months were analyzed. There were 15 patients with anterior uveitis and 20 with posterior and panuveitis. The mean dose of systemic corticosteroids decreased from 12.1 mg/day at baseline to 1.3 mg/day at 6 months and 0.6 mg at 12 months after starting MTX, and approximately 90% of patients were corticosteroid-free at 12 months. The percentage of eyes with inactive uveitis at 6, 12, and 24 months was 49.2%, 59.6%, and 90.0%, respectively. Mean relapse rate score also significantly decreased from 2.88 at baseline to 0.85 at 12 months (
Identifiants
pubmed: 34869426
doi: 10.3389/fmed.2021.732427
pmc: PMC8636923
doi:
Types de publication
Journal Article
Langues
eng
Pagination
732427Informations de copyright
Copyright © 2021 Harada, Hiyama and Kiuchi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ophthalmol Ther. 2014 Dec;3(1-2):17-36
pubmed: 25134495
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Br J Ophthalmol. 1992 Mar;76(3):137-41
pubmed: 1540555
Ocul Immunol Inflamm. 2003 Jun;11(2):131-9
pubmed: 14533032
Ocul Immunol Inflamm. 2020 Aug 20;:1-8
pubmed: 32815752
Korean J Ophthalmol. 2012 Feb;26(1):61-4
pubmed: 22323889
Ophthalmology. 2001 Jun;108(6):1134-9
pubmed: 11382642
Curr Eye Res. 2016;41(2):137-49
pubmed: 25974243
Ophthalmology. 2020 Jun;127(6):826-834
pubmed: 31932091
Arch Ophthalmol. 1984 Dec;102(12):1776-84
pubmed: 6508619
Br J Ophthalmol. 1996 Sep;80(9):844-8
pubmed: 8962842
Pediatr Rheumatol Online J. 2019 Jun 10;17(1):29
pubmed: 31182107
Ophthalmology. 2014 Oct;121(10):1863-70
pubmed: 24917273
RMD Open. 2017 Jan 3;3(1):e000363
pubmed: 28123781
Biomed Res Int. 2015;2015:742792
pubmed: 26558280
Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S145-50
pubmed: 21044449
Br J Ophthalmol. 2019 Oct;103(10):1418-1422
pubmed: 30798264
J Ophthalmic Inflamm Infect. 2013 Jun 01;3(1):49
pubmed: 23724856
Dermatol Clin. 1992 Jul;10(3):505-12
pubmed: 1617809
Am J Ophthalmol. 2019 Dec;208:68-75
pubmed: 31344346
Ophthalmology. 2009 Nov;116(11):2188-98.e1
pubmed: 19748676
Am J Ophthalmol. 2001 May;131(5):647-52
pubmed: 11336942
Arthritis Res Ther. 2019 Jan 5;21(1):2
pubmed: 30611312
Am J Ophthalmol. 2003 Jun;135(6):763-71
pubmed: 12788114
Ocul Immunol Inflamm. 2021 Feb 9;:1-8
pubmed: 33560160
Jpn J Ophthalmol. 2021 Jan;65(1):97-106
pubmed: 33107015
Ocul Immunol Inflamm. 2005 Dec;13(6):415-33
pubmed: 16321886
Surv Ophthalmol. 2013 Jan-Feb;58(1):1-10
pubmed: 23217584
Arch Ophthalmol. 2001 Dec;119(12):1763-9
pubmed: 11735785
Jpn J Ophthalmol. 2012 Jan;56(1):104-6
pubmed: 22042569
Prog Brain Res. 2015;221:243-69
pubmed: 26518082
Mod Rheumatol. 2019 Jan;29(1):31-40
pubmed: 29718746
Br J Ophthalmol. 2019 Feb;103(2):274-278
pubmed: 29666121
JAMA. 2019 Sep 10;322(10):936-945
pubmed: 31503307
Curr Eye Res. 2018 Feb;43(2):254-261
pubmed: 29111815
Am J Ophthalmol Case Rep. 2018 Dec 21;13:122-126
pubmed: 30627688